At a glance
- ARA-290, also called cibinetide, is an 11-amino-acid peptide derived from the three-dimensional structure of erythropoietin. It was designed to study tissue-protective signalling without stimulating red-blood-cell production.
- ARA-290/cibinetide is not an approved medicine. Small clinical studies have explored neuropathy and inflammatory conditions, but they do not establish broad nerve-repair, pain, or tissue-healing benefits for research material.
- Use receptor-complex and erythropoietic controls to test whether a response is separate from classical EPO signalling.
- Measure inflammatory, neuronal, sensory, and haematologic endpoints independently.
What ARA-290 is—and what the name does not establish
ARA-290, also called cibinetide, is an 11-amino-acid peptide derived from the three-dimensional structure of erythropoietin. It was designed to study tissue-protective signalling without stimulating red-blood-cell production.
Cibinetide is proposed to activate an innate-repair receptor complex involving EPOR and CD131, rather than the classical EPO receptor arrangement that drives erythropoiesis. In plain language, it tries to separate EPO’s repair-related signals from its red-cell signal.
Questions to settle before interpreting a result
A useful ARA-290 study begins with material identity, a defined model, a relevant comparator, and an endpoint chosen before the result is known. Broad catalogue language cannot replace those controls.
- Use receptor-complex and erythropoietic controls to test whether a response is separate from classical EPO signalling.
- Measure inflammatory, neuronal, sensory, and haematologic endpoints independently.
- Keep results for the defined clinical candidate cibinetide separate from generic EPO fragments or other ARA-labelled materials.
How to read the ARA-290 evidence
These evidence snapshots summarize the most important distinctions in the published record. They do not combine unlike models or turn an experimental signal into a human-use claim.
Early human evidence
- Design
- Small trials reported signals in neuropathy models
- Finding
- Phase 2 studies in sarcoidosis-associated small-fibre neuropathy reported changes in selected symptoms and nerve measures. Sample size, endpoints, and replication limit broad conclusions.
- Read with care
- This is an interpretation boundary, not a claim that a specific outcome has been established in people.
Mechanism question
- Design
- Repair signalling is proposed to be non-erythropoietic
- Finding
- The central design goal is to avoid red-cell production while retaining tissue-response activity. Blood indices remain useful controls when testing that claim.
- Read with care
- This is an interpretation boundary, not a claim that a specific outcome has been established in people.
What not to assume
- Design
- EPO evidence does not automatically transfer
- Finding
- Cibinetide is a short structural mimic with a proposed receptor distinction. Approved epoetin outcomes and dosing are not evidence for ARA-290.
- Read with care
- This is an interpretation boundary, not a claim that a specific outcome has been established in people.
What the evidence does not establish
ARA-290/cibinetide is not an approved medicine. Small clinical studies have explored neuropathy and inflammatory conditions, but they do not establish broad nerve-repair, pain, or tissue-healing benefits for research material.
Mechanism, cell, animal, observational, and controlled human evidence answer different questions. A positive result at one level cannot be silently promoted to another, and evidence for a sponsor’s defined product does not establish equivalence for an independently sourced research material.
Keep the publication and the vial separate
A published paper identifies its own sequence or chemical identity, formulation, manufacturing context, analytical controls, exposure, and test system. Matching a familiar name on a label is not enough to show that a catalogue vial is the same study material.
For practical research planning, verify the lot-specific identity and documentation, then write the model, comparator, endpoint, and stopping criteria before testing. This guide does not provide preparation, dosing, injection, or human-use instructions.
Sources
Links lead to the paper, official registry, regulator page, or product label used for this guide. Registry records describe protocols and status; they are not treated as positive results.
- ARA 290 in sarcoidosis-associated small-fibre neuropathyPubMed-indexed early human study · 2013
Small early human study with selected symptom and nerve endpoints. Sample size, indication, formulation, and replication limit broader conclusions.
- Think twice before injecting peptides bought online: unauthorized products can seriously harm youHealth Canada · 2026
Official Canadian advisory explaining that a research-use label does not establish authorization, safety, efficacy, or product quality for human use.
Vote for ARA-290
This compound is not currently stocked. Add it to your five-choice catalogue ballot.